NurExone’s 30-for-1 Share Consolidation: A High-Stakes Bet on US Market Access

The arithmetic is stark: thirty shares become one. That is the proposal NurExone Biologic will put before shareholders at its annual and special meeting on September 15, 2026, when investors vote on a reverse stock split of up to 30:1. The consolidation requires approval from at least two-thirds of votes cast, and if passed, would […] The post NurExone’s 30-for-1 Share Consolidation: A High-Stakes…